GB2471523A - Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy - Google Patents

Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy Download PDF

Info

Publication number
GB2471523A
GB2471523A GB0911580A GB0911580A GB2471523A GB 2471523 A GB2471523 A GB 2471523A GB 0911580 A GB0911580 A GB 0911580A GB 0911580 A GB0911580 A GB 0911580A GB 2471523 A GB2471523 A GB 2471523A
Authority
GB
United Kingdom
Prior art keywords
thcv
seizures
cbd
seizure
ptz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0911580A
Other languages
English (en)
Other versions
GB0911580D0 (en
Inventor
Benjamin Whalley
Gary Stephens
Claire Williams
Geoffrey Guy
Stephen Wright
Tetsuro Kikuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Original Assignee
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2471523(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd filed Critical GW Pharma Ltd
Priority to GB0911580A priority Critical patent/GB2471523A/en
Publication of GB0911580D0 publication Critical patent/GB0911580D0/en
Priority to UAA201201092A priority patent/UA108852C2/ru
Priority to PCT/GB2010/051066 priority patent/WO2011001169A1/en
Priority to GB1121919.3A priority patent/GB2485291B/en
Priority to NZ597704A priority patent/NZ597704A/en
Priority to BR112012000076-4A priority patent/BR112012000076A2/pt
Priority to PL10734541.5T priority patent/PL2448637T5/pl
Priority to SI201030622T priority patent/SI2448637T2/sl
Priority to RU2012103603/15A priority patent/RU2563143C2/ru
Priority to HK12105434.9A priority patent/HK1164766B/en
Priority to US13/380,305 priority patent/US9066920B2/en
Priority to MX2012000257A priority patent/MX2012000257A/es
Priority to EP14153495.8A priority patent/EP2727626A1/en
Priority to CN201610808754.9A priority patent/CN106236744A/zh
Priority to GB1010897.5A priority patent/GB2471565B/en
Priority to JP2012516867A priority patent/JP5904938B2/ja
Priority to ES10734541T priority patent/ES2460623T5/es
Priority to DK10734541.5T priority patent/DK2448637T4/da
Priority to CA3040410A priority patent/CA3040410C/en
Priority to PT107345415T priority patent/PT2448637E/pt
Priority to MYPI2011006198A priority patent/MY156759A/en
Priority to KR1020127003123A priority patent/KR101727000B1/ko
Priority to AU2010267775A priority patent/AU2010267775C1/en
Priority to CN2010800310652A priority patent/CN102596322A/zh
Priority to NZ620838A priority patent/NZ620838A/en
Priority to IN804DEN2012 priority patent/IN2012DN00804A/en
Priority to HRP20140398TT priority patent/HRP20140398T4/hr
Priority to EP10734541.5A priority patent/EP2448637B2/en
Priority to CA2766082A priority patent/CA2766082C/en
Priority to EP20175934.7A priority patent/EP3718603A1/en
Priority to SG2011094042A priority patent/SG176914A1/en
Priority to TW099121811A priority patent/TWI461191B/zh
Priority to ARP100102377A priority patent/AR077448A1/es
Publication of GB2471523A publication Critical patent/GB2471523A/en
Priority to IL217280A priority patent/IL217280B/en
Priority to ZA2012/00373A priority patent/ZA201200373B/en
Priority to CY20141100335T priority patent/CY1115338T1/el
Priority to US14/579,061 priority patent/US9522123B2/en
Priority to JP2016050485A priority patent/JP2016166205A/ja
Priority to US15/346,844 priority patent/US20170273913A1/en
Priority to US16/149,983 priority patent/US20190247324A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
GB0911580A 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy Withdrawn GB2471523A (en)

Priority Applications (40)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
EP20175934.7A EP3718603A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phytocannabinoids in the treatment of epilepsy
SG2011094042A SG176914A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
PT107345415T PT2448637E (pt) 2009-07-03 2010-06-29 Utilização de um fitocanabinóide ou de uma combinação de fitocanabinóides no tratamento da epilepsia
KR1020127003123A KR101727000B1 (ko) 2009-07-03 2010-06-29 간질을 치료하기 위한 식물-칸나비노이드의 단독 또는 배합의 용도
GB1121919.3A GB2485291B (en) 2009-07-03 2010-06-29 Cannabidiol for use in the treatment of generalised and/or partial seizures
NZ597704A NZ597704A (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
BR112012000076-4A BR112012000076A2 (pt) 2009-07-03 2010-06-29 Uso de canabidiol na preparação de um medicamento para tratar uma crise parcial e composição compreendendo canabidiol
PL10734541.5T PL2448637T5 (pl) 2009-07-03 2010-06-29 Użycie jednego lub połączenia kannabinoidów roślinnych w leczeniu padaczki
SI201030622T SI2448637T2 (sl) 2009-07-03 2010-06-29 Uporaba enega ali kombinacije fito-kanabinoidov pri zdravljenju epilepsije
RU2012103603/15A RU2563143C2 (ru) 2009-07-03 2010-06-29 Применение одного или комбинации фитоканнабиноидов для лечения эпилепсии
HK12105434.9A HK1164766B (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US13/380,305 US9066920B2 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
MX2012000257A MX2012000257A (es) 2009-07-03 2010-06-29 Uso de uno o una combinacion de fito - cannabinoides en el tratamiento de la epilepsia.
EP14153495.8A EP2727626A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
CN201610808754.9A CN106236744A (zh) 2009-07-03 2010-06-29 植物大麻素中的一种或组合在治疗癫痫中的用途
GB1010897.5A GB2471565B (en) 2009-07-03 2010-06-29 Use of tetrahydrocannabivarin (THCV) in the treatment of epilepsy
JP2012516867A JP5904938B2 (ja) 2009-07-03 2010-06-29 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用
ES10734541T ES2460623T5 (es) 2009-07-03 2010-06-29 Uso de uno o una combinación de fito-canabinoides en el tratamiento de epilepsia
DK10734541.5T DK2448637T4 (da) 2009-07-03 2010-06-29 Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi
CA3040410A CA3040410C (en) 2009-07-03 2010-06-29 Use of tetrahydrocannabivarin in the treatment of generalised seizures
UAA201201092A UA108852C2 (ru) 2009-07-03 2010-06-29 Применение одного или комбинации фито каннабиноидов для лечения эпилепсии
MYPI2011006198A MY156759A (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
CN2010800310652A CN102596322A (zh) 2009-07-03 2010-06-29 植物大麻素中的一种或组合在治疗癫痫中的用途
PCT/GB2010/051066 WO2011001169A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
AU2010267775A AU2010267775C1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
NZ620838A NZ620838A (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
IN804DEN2012 IN2012DN00804A (enExample) 2009-07-03 2010-06-29
HRP20140398TT HRP20140398T4 (hr) 2009-07-03 2010-06-29 Korištenje jednog ili neke kombinacije fitokanabinoida u liječenju epilepsije
EP10734541.5A EP2448637B2 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
CA2766082A CA2766082C (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
ARP100102377A AR077448A1 (es) 2009-07-03 2010-07-02 Uno o una combinacion de fito-canabinoides en el tratamiento de epilepsia
TW099121811A TWI461191B (zh) 2009-07-03 2010-07-02 單種或組合型植物-大麻素於治療癲癇的用途
IL217280A IL217280B (en) 2009-07-03 2011-12-29 Cannabidiol and compositions containing same for use in treating partial seizures
ZA2012/00373A ZA201200373B (en) 2009-07-03 2012-01-17 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
CY20141100335T CY1115338T1 (el) 2009-07-03 2014-05-12 Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας
US14/579,061 US9522123B2 (en) 2009-07-03 2014-12-22 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
JP2016050485A JP2016166205A (ja) 2009-07-03 2016-03-15 てんかんの治療におけるフィトカンナビノイドの１つ又は組合せの使用
US15/346,844 US20170273913A1 (en) 2009-07-03 2016-11-09 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US16/149,983 US20190247324A1 (en) 2009-07-03 2018-10-02 One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
GB0911580D0 GB0911580D0 (en) 2009-08-12
GB2471523A true GB2471523A (en) 2011-01-05

Family

ID=41008705

Family Applications (3)

Application Number Title Priority Date Filing Date
GB0911580A Withdrawn GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB1121919.3A Expired - Fee Related GB2485291B (en) 2009-07-03 2010-06-29 Cannabidiol for use in the treatment of generalised and/or partial seizures
GB1010897.5A Active GB2471565B (en) 2009-07-03 2010-06-29 Use of tetrahydrocannabivarin (THCV) in the treatment of epilepsy

Family Applications After (2)

Application Number Title Priority Date Filing Date
GB1121919.3A Expired - Fee Related GB2485291B (en) 2009-07-03 2010-06-29 Cannabidiol for use in the treatment of generalised and/or partial seizures
GB1010897.5A Active GB2471565B (en) 2009-07-03 2010-06-29 Use of tetrahydrocannabivarin (THCV) in the treatment of epilepsy

Country Status (28)

Country Link
US (4) US9066920B2 (enExample)
EP (3) EP2727626A1 (enExample)
JP (2) JP5904938B2 (enExample)
KR (1) KR101727000B1 (enExample)
CN (2) CN102596322A (enExample)
AR (1) AR077448A1 (enExample)
AU (1) AU2010267775C1 (enExample)
BR (1) BR112012000076A2 (enExample)
CA (2) CA3040410C (enExample)
CY (1) CY1115338T1 (enExample)
DK (1) DK2448637T4 (enExample)
ES (1) ES2460623T5 (enExample)
GB (3) GB2471523A (enExample)
HR (1) HRP20140398T4 (enExample)
IL (1) IL217280B (enExample)
IN (1) IN2012DN00804A (enExample)
MX (1) MX2012000257A (enExample)
MY (1) MY156759A (enExample)
NZ (2) NZ620838A (enExample)
PL (1) PL2448637T5 (enExample)
PT (1) PT2448637E (enExample)
RU (1) RU2563143C2 (enExample)
SG (1) SG176914A1 (enExample)
SI (1) SI2448637T2 (enExample)
TW (1) TWI461191B (enExample)
UA (1) UA108852C2 (enExample)
WO (1) WO2011001169A1 (enExample)
ZA (1) ZA201200373B (enExample)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712A (en) * 2011-01-04 2012-08-08 Gw Pharma Ltd Use of the cannabidiol (CBD) in combination with a standard anti-epileptic drug, for the treatment of epilepsy
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US9066920B2 (en) 2009-07-03 2015-06-30 Gw Pharma Limited Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US9125859B2 (en) 2010-03-30 2015-09-08 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US9474726B2 (en) 2014-06-17 2016-10-25 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10092525B2 (en) 2014-10-14 2018-10-09 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10583096B2 (en) 2016-03-31 2020-03-10 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10709671B2 (en) 2015-06-17 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10729665B2 (en) 2011-09-29 2020-08-04 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10765643B2 (en) 2014-10-14 2020-09-08 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10918608B2 (en) 2014-10-14 2021-02-16 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11065227B2 (en) 2016-08-25 2021-07-20 GW Research Limited Use of cannabinoids in the treatment of multiple myeloma
US11147776B2 (en) 2014-06-27 2021-10-19 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US11147783B2 (en) 2015-08-10 2021-10-19 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11229612B2 (en) 2016-07-01 2022-01-25 GW Research Limited Parenteral formulations
US11291631B2 (en) 2016-07-01 2022-04-05 GW Research Limited Oral cannabinoid formulations
US11351152B2 (en) 2016-06-15 2022-06-07 India Globalization Capital, Inc. Method and composition for treating seizure disorders
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US11679087B2 (en) 2016-12-16 2023-06-20 GW Research Limited Use of cannabinoids in the treatment of Angelman syndrome
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
US12161607B2 (en) 2017-02-27 2024-12-10 Jazz Pharmaceuticals Research Uk Limited Combination of cannabinoids in the treatment of leukemia
US12263139B2 (en) 2017-06-23 2025-04-01 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of tuberous sclerosis complex
US12383567B2 (en) 2017-12-01 2025-08-12 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US11062795B2 (en) 2007-03-02 2021-07-13 Enigami Systems, Inc. Healthcare data system
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
EP3247359A4 (en) 2015-01-25 2018-08-08 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016123475A1 (en) 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
WO2016160542A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
EP3288592A4 (en) * 2015-04-28 2019-01-09 The Regents of The University of California USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
JP2022547136A (ja) * 2019-09-17 2022-11-10 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 発達性及びてんかん性脳症における行動障害の治療
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
CN118510544A (zh) 2021-07-29 2024-08-16 爱莫里大学 大麻素类的磷酸酯前药
JP2025512495A (ja) * 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
WO2009007697A1 (en) * 2007-07-06 2009-01-15 Gw Pharma Limited New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
PL215220B1 (pl) * 2002-08-14 2013-11-29 Gw Pharma Ltd Ciekly preparat farmaceutyczny
JP4657716B2 (ja) 2002-08-14 2011-03-23 ジーダブリュー・ファーマ・リミテッド 植物材料からの薬学的に活性な成分の抽出の改良
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US9877928B2 (en) 2006-05-30 2018-01-30 Air Systems, Inc. Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
ES2727648T3 (es) 2008-03-26 2019-10-17 Stichting Sanammad Composiciones de goma de mascar que comprenden cannabinoides
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
RU2639120C2 (ru) 2011-08-26 2017-12-19 Биал-Портела Энд Ка, С.А. Лечение с использованием ацетата эсликарбазепина или эсликарбазепина
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
MX387604B (es) 2014-05-29 2025-03-18 Insys Pharma Inc Formulaciones cannabinoides estables.
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
WO2009007697A1 (en) * 2007-07-06 2009-01-15 Gw Pharma Limited New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066920B2 (en) 2009-07-03 2015-06-30 Gw Pharma Limited Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US9522123B2 (en) 2009-07-03 2016-12-20 Gw Pharma Limited Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US10799467B2 (en) 2010-03-30 2020-10-13 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US9125859B2 (en) 2010-03-30 2015-09-08 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US12023305B2 (en) 2010-03-30 2024-07-02 Gw Pharma Limited Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US12357586B2 (en) 2011-01-04 2025-07-15 Jazz Pharmaceuticals Research Uk Limited Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2487712A (en) * 2011-01-04 2012-08-08 Gw Pharma Ltd Use of the cannabidiol (CBD) in combination with a standard anti-epileptic drug, for the treatment of epilepsy
US10729665B2 (en) 2011-09-29 2020-08-04 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US12121499B2 (en) 2011-09-29 2024-10-22 Gw Pharma Ltd. Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11318109B2 (en) 2011-09-29 2022-05-03 Gw Pharma Limited Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9956183B2 (en) 2014-06-17 2018-05-01 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US9956186B2 (en) 2014-06-17 2018-05-01 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US9956184B2 (en) 2014-06-17 2018-05-01 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11311498B2 (en) 2014-06-17 2022-04-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11701330B2 (en) 2014-06-17 2023-07-18 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US9956185B2 (en) 2014-06-17 2018-05-01 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11766411B2 (en) 2014-06-17 2023-09-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US9949936B2 (en) 2014-06-17 2018-04-24 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10603288B2 (en) 2014-06-17 2020-03-31 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11963937B2 (en) 2014-06-17 2024-04-23 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11154516B2 (en) 2014-06-17 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US9949937B2 (en) 2014-06-17 2018-04-24 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US9474726B2 (en) 2014-06-17 2016-10-25 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11147776B2 (en) 2014-06-27 2021-10-19 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US11793770B2 (en) 2014-06-27 2023-10-24 GW Research Limited 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
US10137095B2 (en) 2014-10-14 2018-11-27 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10918608B2 (en) 2014-10-14 2021-02-16 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10966939B2 (en) 2014-10-14 2021-04-06 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11065209B2 (en) 2014-10-14 2021-07-20 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11633369B2 (en) 2014-10-14 2023-04-25 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11096905B2 (en) 2014-10-14 2021-08-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11446258B2 (en) 2014-10-14 2022-09-20 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11400055B2 (en) 2014-10-14 2022-08-02 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US11154517B2 (en) 2014-10-14 2021-10-26 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10709673B2 (en) 2014-10-14 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12318356B2 (en) 2014-10-14 2025-06-03 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US10849860B2 (en) 2014-10-14 2020-12-01 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10709674B2 (en) 2014-10-14 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12427160B2 (en) 2014-10-14 2025-09-30 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US10765643B2 (en) 2014-10-14 2020-09-08 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US10111840B2 (en) 2014-10-14 2018-10-30 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US10092525B2 (en) 2014-10-14 2018-10-09 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
US11357741B2 (en) 2015-06-17 2022-06-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10709671B2 (en) 2015-06-17 2020-07-14 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US12064399B2 (en) 2015-06-17 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11684598B2 (en) 2015-08-10 2023-06-27 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11147783B2 (en) 2015-08-10 2021-10-19 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US10583096B2 (en) 2016-03-31 2020-03-10 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11351152B2 (en) 2016-06-15 2022-06-07 India Globalization Capital, Inc. Method and composition for treating seizure disorders
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10383892B2 (en) 2016-06-29 2019-08-20 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10537592B2 (en) 2016-06-29 2020-01-21 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US12213985B2 (en) 2016-07-01 2025-02-04 Jazz Pharmaceuticals Research Uk Limited Oral cannabinoid formulations
US12064398B2 (en) 2016-07-01 2024-08-20 Jazz Pharmaceuticals Research Uk Limited Parenteral formulations
US11291631B2 (en) 2016-07-01 2022-04-05 GW Research Limited Oral cannabinoid formulations
US11229612B2 (en) 2016-07-01 2022-01-25 GW Research Limited Parenteral formulations
US11065227B2 (en) 2016-08-25 2021-07-20 GW Research Limited Use of cannabinoids in the treatment of multiple myeloma
US11679087B2 (en) 2016-12-16 2023-06-20 GW Research Limited Use of cannabinoids in the treatment of Angelman syndrome
US11426362B2 (en) 2017-02-17 2022-08-30 GW Research Limited Oral cannabinoid formulations
US12161607B2 (en) 2017-02-27 2024-12-10 Jazz Pharmaceuticals Research Uk Limited Combination of cannabinoids in the treatment of leukemia
US12263139B2 (en) 2017-06-23 2025-04-01 Jazz Pharmaceuticals Research Uk Limited Use of cannabidiol in the treatment of tuberous sclerosis complex
US12383567B2 (en) 2017-12-01 2025-08-12 Jazz Pharmaceuticals Research Uk Limited Use of cannabinoids in the treatment of epilepsy
US11806319B2 (en) 2018-01-03 2023-11-07 GW Research Limited Pharmaceutical composition comprising a cannabinoid
US12102619B2 (en) 2020-02-27 2024-10-01 Jazz Pharmaceuticals Research Uk Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160795B2 (en) 2020-02-27 2021-11-02 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11406623B2 (en) 2020-02-27 2022-08-09 GW Research Limited Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Also Published As

Publication number Publication date
AR077448A1 (es) 2011-08-31
CA3040410A1 (en) 2011-01-06
CN106236744A (zh) 2016-12-21
GB2471565B (en) 2012-07-04
GB2471565A (en) 2011-01-05
CA2766082A1 (en) 2011-01-06
DK2448637T4 (da) 2022-09-12
GB2485291B (en) 2013-03-27
ZA201200373B (en) 2012-09-26
HRP20140398T1 (hr) 2014-06-20
MX2012000257A (es) 2012-01-27
PL2448637T5 (pl) 2022-10-03
SI2448637T2 (sl) 2022-10-28
EP2448637B2 (en) 2022-06-08
GB2485291A (en) 2012-05-09
JP5904938B2 (ja) 2016-04-20
CA3040410C (en) 2023-03-28
AU2010267775C1 (en) 2020-02-27
IL217280B (en) 2018-05-31
TWI461191B (zh) 2014-11-21
US20190247324A1 (en) 2019-08-15
SG176914A1 (en) 2012-01-30
KR20120088648A (ko) 2012-08-08
ES2460623T5 (es) 2022-10-14
AU2010267775A1 (en) 2012-02-23
HRP20140398T4 (hr) 2022-10-14
US20170273913A1 (en) 2017-09-28
EP2448637B1 (en) 2014-03-12
JP2012532093A (ja) 2012-12-13
BR112012000076A2 (pt) 2020-06-02
IN2012DN00804A (enExample) 2015-06-26
US20120165402A1 (en) 2012-06-28
US9522123B2 (en) 2016-12-20
US20150335590A1 (en) 2015-11-26
EP2727626A1 (en) 2014-05-07
DK2448637T3 (da) 2014-05-26
EP3718603A1 (en) 2020-10-07
GB201121919D0 (en) 2012-02-01
EP2448637A1 (en) 2012-05-09
CY1115338T1 (el) 2017-01-04
WO2011001169A1 (en) 2011-01-06
CN102596322A (zh) 2012-07-18
US9066920B2 (en) 2015-06-30
AU2010267775B2 (en) 2016-10-06
RU2563143C2 (ru) 2015-09-20
IL217280A0 (en) 2012-02-29
HK1164766A1 (en) 2012-09-28
GB0911580D0 (en) 2009-08-12
KR101727000B1 (ko) 2017-05-02
GB201010897D0 (en) 2010-08-11
NZ620838A (en) 2015-08-28
SI2448637T1 (sl) 2014-07-31
PL2448637T3 (pl) 2014-08-29
UA108852C2 (ru) 2015-06-25
CA2766082C (en) 2019-06-11
MY156759A (en) 2016-03-31
PT2448637E (pt) 2014-05-27
TW201105318A (en) 2011-02-16
RU2012103603A (ru) 2013-08-10
ES2460623T3 (es) 2014-05-14
JP2016166205A (ja) 2016-09-15
NZ597704A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
GB2471523A (en) Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
EP2661263B1 (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
AU2012204800A1 (en) Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2479153A (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
HK40040800A (en) Use of one or a combination of phytocannabinoids in the treatment of epilepsy
HK1195750A (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
HK1164766B (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
HK40048801A (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
HK1187543B (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
HK1187543A (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)